{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:09:13Z","timestamp":1790665753264,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017784","name":"Gilead Research Scholars Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejphar.2022.175396","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T21:01:17Z","timestamp":1668805277000},"page":"175396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Identification of novel F508del-CFTR traffic correctors among triazole derivatives"],"prefix":"10.1016","volume":"938","author":[{"given":"Mafalda","family":"Bacalhau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa C.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe R.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f4nica D.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 S.","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida D.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla D.","family":"Buarque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-9359","authenticated-orcid":false,"given":"Miqu\u00e9ias","family":"Lopes-Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.175396_bib1","doi-asserted-by":"crossref","first-page":"7813","DOI":"10.1007\/s00018-021-03994-5","article-title":"Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR","volume":"78","author":"Baatallah","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejphar.2022.175396_bib2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1113\/jphysiol.2005.096669","article-title":"Failure of cAMP agonists to activate rescued \u0394F508 CFTR in CFBE41o- airway epithelial monolayers","volume":"569","author":"Bebok","year":"2005","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejphar.2022.175396_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2022.175396_bib4","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.drudis.2017.05.014","article-title":"The 1,2,3-triazole ring as a bioisostere in medicinal chemistry","volume":"22","author":"Bonandi","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2022.175396_bib5","doi-asserted-by":"crossref","first-page":"9038","DOI":"10.1038\/srep09038","article-title":"Protein traffic disorders : an effective high-throughput fluorescence microscopy pipeline for drug discovery","volume":"12","author":"Botelho","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2022.175396_bib6","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.3390\/ijms22105262","article-title":"Partial rescue of f508del-cftr stability and trafficking defects by double corrector treatment","volume":"22","author":"Capurro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2022.175396_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1097-2765(00)80196-3","article-title":"Removal of multiple arginine-framed trafficking signals overcomes misprocessing of \u0394F508 CFTR present in most patients with cystic fibrosis","volume":"4","author":"Chang","year":"1999","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejphar.2022.175396_bib8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of FDA and EMA regulatory decision - making process on the access to CFTR modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejphar.2022.175396_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bioorg.2018.10.003","article-title":"Design, synthesis, structural characterization and in vitro evaluation of new 1,4-disubstituted-1,2,3-triazole derivatives against glioblastoma cells","volume":"83","author":"da Silva","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejphar.2022.175396_bib10","first-page":"1258","article-title":"New \u03b1-Hydroxy-1,2,3-triazoles and 9H-Fluorenes-1,2,3-triazolesSynthesis and evaluation as Glycine transporter 1 inhibitors","volume":"31","author":"da Silva","year":"2020","journal-title":"J. Brazilian Chem. Soc"},{"key":"10.1016\/j.ejphar.2022.175396_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2022.175396_bib12","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/354526a0","article-title":"Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation","volume":"354","author":"Dalemans","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2022.175396_bib13","doi-asserted-by":"crossref","first-page":"35896","DOI":"10.1074\/jbc.M205644200","article-title":"Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator \u03b4F508","volume":"277","author":"Decarvalho","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2022.175396_bib14","doi-asserted-by":"crossref","first-page":"344ra84","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2022.175396_bib15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/358761a0","article-title":"Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive","volume":"358","author":"Denning","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2022.175396_bib16","doi-asserted-by":"crossref","first-page":"W337","DOI":"10.1093\/nar\/gkx333","article-title":"ProteinsPlus: a web portal for structure analysis of macromolecules","volume":"45","author":"F\u00e4hrrolfes","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2022.175396_bib17","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.chembiol.2013.06.004","article-title":"Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction","volume":"20","author":"Farinha","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejphar.2022.175396_bib18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","article-title":"Mechanism of CFTR correction by type I folding correctors","volume":"185","author":"Fiedorczuk","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2022.175396_bib19","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.cell.2011.07.021","article-title":"Rescue of \u0394F508-CFTR trafficking via a GRASP-dependent unconventional secretion pathway","volume":"146","author":"Gee","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2022.175396_bib20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/mol.117.108373","article-title":"Direct binding of the corrector VX-809 to human CFTR NBD1: evidence of an allosteric coupling between the binding site and the NBD1:CL4 interface s","volume":"92","author":"Hudson","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175396_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0092-8674(95)90241-4","article-title":"Multiple proteolytic systems, including the proteasome, contribute to CFTR processing","volume":"83","author":"Jensen","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2022.175396_bib22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/tra.12403","article-title":"Monomerization and ER relocalization of GRASP is a requisite for unconventional secretion of CFTR","volume":"17","author":"Kim","year":"2016","journal-title":"Traffic"},{"key":"10.1016\/j.ejphar.2022.175396_bib23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fphar.2012.00201","article-title":"Mechanisms of CFTR folding at the endoplasmic reticulum","volume":"3","author":"Kim","year":"2012","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175396_bib24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/sj.emboj.7600040","article-title":"Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator","volume":"23","author":"Lewis","year":"2004","journal-title":"EMBO J."},{"key":"10.1016\/j.ejphar.2022.175396_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejphar.2022.175396_bib26","first-page":"1184","article-title":"Structural identification of a hotspot on CFTR for potentiation","volume":"364","author":"Liu","year":"2019","journal-title":"Science 84"},{"key":"10.1016\/j.ejphar.2022.175396_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bcp.2017.03.020","article-title":"Corrector VX-809 promotes interactions between cytoplasmic loop one and the first nucleotide-binding domain of CFTR","volume":"136","author":"Loo","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175396_bib28","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175396_bib29","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3390\/cells11010136","article-title":"Rescue of mutant CFTR trafficking defect by the investigational compound MCG1516A","volume":"11","author":"Lopes-Pacheco","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2022.175396_bib30","doi-asserted-by":"crossref","first-page":"25636","DOI":"10.1074\/jbc.M115.671925","article-title":"Combination of correctors rescue \u0394F508-CFTR by reducing its association with Hsp 40 and Hsp 27","volume":"290","author":"Lopes-Pacheco","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2022.175396_bib31","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1159\/000475578","article-title":"Combination of correctors rescues CFTR transmembrane-domain mutants by mitigating their interactions with proteostasis","volume":"41","author":"Lopes-Pacheco","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2022.175396_bib32","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17460441.2021.1912732","article-title":"Discovery of CFTR modulators for the treatment of cystic fibrosis","volume":"16","author":"Lopes-Pacheco","year":"2021","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejphar.2022.175396_bib33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/cbic.201500620","article-title":"Correctors rescue CFTR mutations in nucleotide-binding domain 1 (NBD1) by modulating proteostasis","volume":"17","author":"Lopes-Pacheco","year":"2016","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejphar.2022.175396_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114133","article-title":"Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR","volume":"180","author":"Lopes-Pacheco","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175396_bib35","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.175396_bib36","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1172\/JCI24898","article-title":"Small-molecule correctors of defective \u0394F508-CFTR cellular processing identified by high-throughput screening","volume":"115","author":"Pedemonte","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2022.175396_bib37","doi-asserted-by":"crossref","first-page":"C866","DOI":"10.1152\/ajpcell.00404.2009","article-title":"Influence of cell background on pharmacological rescue of mutant CFTR","volume":"298","author":"Pedemonte","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejphar.2022.175396_bib38","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/JEP.S255377","article-title":"Pharmacological modulation of ion channels for the treatment of cystic fibrosis","volume":"13","author":"Pinto","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175396_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101615","article-title":"Can two wrongs make a right? F508del-CFTR ion channel rescue by second-site mutations in its transmembrane domains","volume":"298","author":"Prins","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2022.175396_bib40","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cell.2011.11.024","article-title":"Correction of both NBD1 energetics and domain interface is required to restore \u0394F508 CFTR folding and function","volume":"148","author":"Rabeh","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2022.175396_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/ijms23010024","article-title":"Rare trafficking cftr mutations involve distinct cellular retention machineries and require different rescuing strategies","volume":"23","author":"Ramalho","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2022.175396_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119796","article-title":"Rescue of NBD2 mutants N1303K and S1235R of CFTR by small-molecule correctors and transcomplementation","volume":"10","author":"Rapino","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2022.175396_bib43","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1091\/mbc.e13-05-0240","article-title":"VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1","volume":"24","author":"Ren","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ejphar.2022.175396_bib44","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2022.175396_bib45","doi-asserted-by":"crossref","first-page":"17891","DOI":"10.1073\/pnas.0608312103","article-title":"Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms","volume":"103","author":"Roxo-Rosa","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2022.175396_bib46","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1091\/mbc.e09-05-0427","article-title":"Interplay between ER exit code and domain conformation in CFTR misprocessing and rescue","volume":"21","author":"Roy","year":"2010","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ejphar.2022.175396_bib47","doi-asserted-by":"crossref","first-page":"W48","DOI":"10.1093\/nar\/gkaa235","article-title":"ProteinsPlus: interactive analysis of protein\u2013ligand binding interfaces","volume":"48","author":"Sch\u00f6ning-Stierand","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2022.175396_bib48","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1074\/jbc.M009172200","article-title":"Conformational and temperature-sensitive stability defects of the \u0394F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments","volume":"276","author":"Sharma","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2022.175396_bib49","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/362160a0","article-title":"Mutations in CFTR associated with mild-disease-form CI- channels with altered pore properties","volume":"362","author":"Sheppard","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2022.175396_bib50","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3390\/jpm12081321","article-title":"Advances in preclinical in vitro models for the translation of precision medicine for cystic fibrosis","volume":"12","author":"Silva","year":"2022","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.ejphar.2022.175396_bib51","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3390\/jpm11050421","article-title":"Personalized medicine based on nasal epithelial cells: comparative studies with rectal biopsies and intestinal organoids","volume":"11","author":"Silva","year":"2021","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.ejphar.2022.175396_bib52","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1124\/jpet.119.261800","article-title":"Biological characterization of F508DelCFTR protein processing by the CFTR corrector ABBV-2222\/GLPG2222","volume":"372","author":"Singh","year":"2020","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2022.175396_bib53","doi-asserted-by":"crossref","first-page":"C872","DOI":"10.1152\/ajpcell.00507.2010","article-title":"Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling","volume":"301","author":"Sondo","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejphar.2022.175396_bib54","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejphar.2022.175396_bib55","doi-asserted-by":"crossref","first-page":"35825","DOI":"10.1074\/jbc.M110.131623","article-title":"The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis","volume":"285","author":"Thibodeau","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2022.175396_bib56","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1021\/jm051197e","article-title":"MolDock: a new technique for high-accuracy molecular docking","volume":"49","author":"Thomsen","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2022.175396_bib57","doi-asserted-by":"crossref","first-page":"L1117","DOI":"10.1152\/ajplung.00169.2005","article-title":"Rescue of \u0394F508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules","volume":"290","author":"Van Goor","year":"2006","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.ejphar.2022.175396_bib58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejphar.2022.175396_bib59","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejphar.2022.175396_bib60","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3390\/jpm11070643","article-title":"A precision medicine approach to optimize modulator therapy for rare cftr folding mutants","volume":"11","author":"Veit","year":"2021","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.ejphar.2022.175396_bib61","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41591-018-0200-x","article-title":"Structure-guided combination therapy to potently improve the function of mutant CFTRs","volume":"24","author":"Veit","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2022.175396_bib62","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1021\/ci100241y","article-title":"Analyzing the topology of active sites: on the prediction of pockets and subpockets","volume":"50","author":"Volkamer","year":"2010","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejphar.2022.175396_bib63","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1021\/ci200454v","article-title":"Combining global and local measures for structure-based druggability predictions","volume":"52","author":"Volkamer","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejphar.2022.175396_bib64","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.drudis.2015.08.004","article-title":"Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries","volume":"21","author":"Wang","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2022.175396_bib65","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1111\/j.1600-0854.2008.00806.x","article-title":"Chemical and biological folding contribute to temperature sensitive \u0394F508 CFTR Trafficking.pdf","volume":"9","author":"Wang","year":"2008","journal-title":"Traffic"},{"key":"10.1016\/j.ejphar.2022.175396_bib66","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1083\/jcb.200401035","article-title":"COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code","volume":"167","author":"Wang","year":"2004","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejphar.2022.175396_bib67","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fphar.2012.00176","article-title":"Ouabain mimics low temperature rescue of F508del-CFTR in cystic fibrosis epithelial cells","volume":"3","author":"Zhang","year":"2012","journal-title":"Front. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922006574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922006574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:10:35Z","timestamp":1757977835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922006574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":67,"alternative-id":["S0014299922006574"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175396","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of novel F508del-CFTR traffic correctors among triazole derivatives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175396","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"175396"}}